Mesa Laboratories Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Mesa Laboratories wird ein jährliches Gewinn- und Umsatzwachstum von 134.3% bzw. 5.6% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 134.5% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 27.2% betragen.

Wichtige Informationen

134.3%

Wachstumsrate der Gewinne

134.5%

EPS-Wachstumsrate

Life Sciences Gewinnwachstum18.4%
Wachstumsrate der Einnahmen5.6%
Zukünftige Eigenkapitalrendite27.2%
Analystenabdeckung

Low

Zuletzt aktualisiert21 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Mesa Laboratories, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Feb 08
Mesa Laboratories, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Recent updates

Investors Give Mesa Laboratories, Inc. (NASDAQ:MLAB) Shares A 25% Hiding

Nov 20
Investors Give Mesa Laboratories, Inc. (NASDAQ:MLAB) Shares A 25% Hiding

We Think Mesa Laboratories (NASDAQ:MLAB) Can Stay On Top Of Its Debt

Oct 17
We Think Mesa Laboratories (NASDAQ:MLAB) Can Stay On Top Of Its Debt

A Piece Of The Puzzle Missing From Mesa Laboratories, Inc.'s (NASDAQ:MLAB) 27% Share Price Climb

Jul 29
A Piece Of The Puzzle Missing From Mesa Laboratories, Inc.'s (NASDAQ:MLAB) 27% Share Price Climb

Is Now An Opportune Moment To Examine Mesa Laboratories, Inc. (NASDAQ:MLAB)?

May 03
Is Now An Opportune Moment To Examine Mesa Laboratories, Inc. (NASDAQ:MLAB)?

Is Mesa Laboratories (NASDAQ:MLAB) Using Too Much Debt?

Mar 15
Is Mesa Laboratories (NASDAQ:MLAB) Using Too Much Debt?

Mesa Laboratories, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Feb 08
Mesa Laboratories, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Is Mesa Laboratories, Inc. (NASDAQ:MLAB) Trading At A 43% Discount?

Dec 05
Is Mesa Laboratories, Inc. (NASDAQ:MLAB) Trading At A 43% Discount?

Is Mesa Laboratories (NASDAQ:MLAB) A Risky Investment?

Sep 28
Is Mesa Laboratories (NASDAQ:MLAB) A Risky Investment?

Estimating The Intrinsic Value Of Mesa Laboratories, Inc. (NASDAQ:MLAB)

Aug 09
Estimating The Intrinsic Value Of Mesa Laboratories, Inc. (NASDAQ:MLAB)

We Think Mesa Laboratories (NASDAQ:MLAB) Is Taking Some Risk With Its Debt

Jun 28
We Think Mesa Laboratories (NASDAQ:MLAB) Is Taking Some Risk With Its Debt

Investor Optimism Abounds Mesa Laboratories, Inc. (NASDAQ:MLAB) But Growth Is Lacking

May 31
Investor Optimism Abounds Mesa Laboratories, Inc. (NASDAQ:MLAB) But Growth Is Lacking

A Look At The Intrinsic Value Of Mesa Laboratories, Inc. (NASDAQ:MLAB)

Apr 12
A Look At The Intrinsic Value Of Mesa Laboratories, Inc. (NASDAQ:MLAB)

Does Mesa Laboratories (NASDAQ:MLAB) Have A Healthy Balance Sheet?

Mar 13
Does Mesa Laboratories (NASDAQ:MLAB) Have A Healthy Balance Sheet?

Estimating The Fair Value Of Mesa Laboratories, Inc. (NASDAQ:MLAB)

Dec 20
Estimating The Fair Value Of Mesa Laboratories, Inc. (NASDAQ:MLAB)

Mesa Laboratories declares $0.16 dividend

Oct 03

Mesa Laboratories: Softening Bottom Line Fundamentals, Fairly Priced

Sep 09

Are Investors Undervaluing Mesa Laboratories, Inc. (NASDAQ:MLAB) By 41%?

Sep 06
Are Investors Undervaluing Mesa Laboratories, Inc. (NASDAQ:MLAB) By 41%?

Does Mesa Laboratories (NASDAQ:MLAB) Have A Healthy Balance Sheet?

Aug 08
Does Mesa Laboratories (NASDAQ:MLAB) Have A Healthy Balance Sheet?

Mesa Laboratories GAAP EPS of -$0.27 misses by $0.27, revenue of $50.45M misses by $1.72M

Aug 04

Mesa Laboratories declares $0.16 dividend

Jul 07

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:MLAB - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
3/31/20272631443532
3/31/2026248841474
3/31/20252351030364
9/30/2024228-2463640N/A
6/30/2024224-2504145N/A
3/31/2024216-2544244N/A
12/31/202321314144N/A
9/30/2023214-13640N/A
6/30/202321923641N/A
3/31/202321912328N/A
12/31/2022222-12025N/A
9/30/2022223-42833N/A
6/30/2022200-22327N/A
3/31/202218423539N/A
12/31/202116383943N/A
9/30/202114353638N/A
6/30/202113944244N/A
3/31/202113433537N/A
12/31/2020130-23132N/A
9/30/2020128-23132N/A
6/30/2020121-22729N/A
3/31/202011822527N/A
12/31/201911052728N/A
9/30/2019105102728N/A
6/30/201910482425N/A
3/31/201910372931N/A
12/31/2018104102830N/A
9/30/2018101-22729N/A
6/30/2018990N/A30N/A
3/31/201896-3N/A26N/A
12/31/201794-4N/A17N/A
9/30/20179411N/A14N/A
6/30/20179511N/A7N/A
3/31/20179411N/A17N/A
12/31/20169412N/A14N/A
9/30/20169011N/A9N/A
6/30/20168810N/A18N/A
3/31/20168511N/A17N/A
12/31/2015789N/A15N/A
9/30/2015769N/A16N/A
6/30/20157310N/A13N/A
3/31/20157110N/A11N/A
12/31/20146811N/A9N/A
9/30/20146410N/A11N/A
6/30/2014589N/A10N/A
3/31/2014539N/A12N/A
12/31/2013508N/A12N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: MLAB wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (2.6%).

Ertrag vs. Markt: MLAB wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: MLAB wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: MLABDie Einnahmen des Unternehmens (5.6% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (8.9% pro Jahr).

Hohe Wachstumseinnahmen: MLABDie Einnahmen des Unternehmens (5.6% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.


Wachstumsprognosen für den Gewinn je Aktie


Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: MLABDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (27.2%)


Wachstumsunternehmen entdecken